Exhibit 10.1
Executive Compensation and Equity Awards
At a meeting of the Compensation Committee of the Board of Directors of Allos Therapeutics, Inc. (the “Company”) held on February 22, 2010, the Compensation Committee (a) determined and approved 2009 cash bonus awards and 2010 base salaries and target bonus awards (expressed as a percentage of base salary) for the Company’s “named executive officers” (as defined in Item 402(a)(3) of Regulation S-K promulgated by the Securities and Exchange Commission), and (b) granted stock options and restricted stock units to the Company’s named executive officers pursuant to the Company’s 2008 Equity Incentive Plan, in each case, as set forth in the table below. The 2009 cash bonus award and 2010 target bonus award (expressed as a percentage of base salary) for the Company’s Chief Executive Officer was also reviewed and approved by the full Board of Directors at a meeting held on February 22 and 23, 2010.
Name and Title | | 2009
Bonus
Award | | 2010
Base
Salary | | 2010
Target
Bonus (%) | | Stock
Options | | Restricted
Stock Units | |
Paul L. Berns
President and Chief Executive Officer | | $ | 340,703 | | $ | 550,000 | | 75 | % | 170,000 | | 100,000 | |
James V. Caruso
Executive Vice President, Chief Commercial Officer | | $ | 183,521 | | $ | 426,929 | | 50 | % | 102,300 | | 58,254 | |
Marc H. Graboyes
Senior Vice President, General Counsel and Secretary | | $ | 137,418 | | $ | 321,192 | | 50 | % | 73,083 | | 41,617 | |
Bruce K. Bennett
Vice President, Pharmaceutical Operations | | $ | 66,951 | | $ | 245,180 | | 30 | % | 31,500 | | 17,937 | |
David C. Clark
Vice President, Finance and Treasurer | | $ | 59,789 | | $ | 236,775 | | 30 | % | 26,250 | | 14,948 | |
